IND-enabling studies of the potent LpxC inhibitor LPC-233 as a novel antibiotic against Gram-negative pathogens
Research Grant
Administered By
Biochemistry
Awarded By
Valanbio Therapeutics, Inc.
Start Date
April 1, 2020
End Date
September 30, 2022
Administered By
Biochemistry
Awarded By
Valanbio Therapeutics, Inc.
Start Date
April 1, 2020
End Date
September 30, 2022